Clinical trials: Erythema Multiforme, open to volunteers
Breast Cancer, Axillary Lymph Nodes
Using LUminoMark vs Coventional Practice for Targeted Axillary Surgery
The purpose of this study was to compare the use of LuminoMarkTM as a method of targeting axillary lymph nodes with other existing methods used in each institution, such as charcoal staining, needle targeting, and…
- Conditions
- Breast Cancer, Axillary Lymph Nodes, Target Lesion
- Trial name
- LUCAS (NCT06903429)
- Testing
- Targeting of axillary lymph nodes using LuminoMark, Targeting of axillary lymph nodes using conventional method
- Volunteers
- 330 people
- Sponsor
- Kyungpook National University Chilgok Hospital
Gout Initiating Urate-loweringUrate-lowering Therapy, Gout Arthritis
HLA-B*58:01-Guided Therapy for Gout: Effectiveness, Safety, and Cost-Effectiveness
Severe cutaneous adverse reactions (SCARs), such as Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) and drug reaction with eosinophilia and systemic symptoms (DRESS), are rare but life-threatening complications that…
- Conditions
- Gout Initiating Urate-loweringUrate-lowering Therapy, Gout Arthritis, Gout and Hyperuricemia
- Trial name
- HLA-SCREEN (NCT07369622)
- Testing
- HLA-B*58:01 Genotyping, Allopurinol Tablet, Febuxostat
- Volunteers
- 228 people, healthy volunteers welcome
- Sponsor
- Haiphong University of Medicine and Pharmacy
Toxic Epidermal Necrolysis, Immunotherapy
New Therapeutic Target for Toxic Epidermal Necrolysis (TEN) Using Anti-CD38+ Monoclonal Antibodies.
Toxic Epidermal Necrolysis (TEN) are rare diseases that are dermatologic emergencies characterized by widespread epidermal necrosis and sloughing of skin. A hundred patients are affected each year in France.
- Conditions
- Toxic Epidermal Necrolysis, Immunotherapy, Cutaneous Adverse Drug Reactions (CADR)
- Trial name
- NET-CD38 (NCT07110662)
- Testing
- DARATUMUMAB (DARZALEX®)
- Where
- France
- Volunteers
- 9 people
- Sponsor
- Hospices Civils de Lyon
Stevens-Johnson Syndrome, Lyell Syndrome
Drug Reactions Sampling (COLLECTIONTOXIDERMIES)
Intro: Dermatology department of Henri Mondor Hospital (Creteil, France), is a reference center for toxic bullous diseases and severe cutaneous drug reactions (Stevens-Johnson syndrome (SJS), Lyell syndrome (toxic epidermal…
- Conditions
- Stevens-Johnson Syndrome, Lyell Syndrome, Drug Reactions, AGEP
- Trial name
- NCT03659227
- Where
- France
- Volunteers
- 500 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Erythema Multiforme
Severe Erythema Multiforme - CORTICO
Erythema multiforme (EM) is an acute and often recurrent mucocutaneous disease. EM is considered a hypersensitivity immune-mediated reaction.
- Trial name
- SEMCORTICO (NCT06266221)
- Testing
- Prednisone 20 Mg, Methylprednisolone 120 Mg
- Volunteers
- 96 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Epidermal Necrolysis, Lyell Syndrome
LYell SYndrome MEsenchymal Stromal Cells Treatment
Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are rare severe cutaneous adverse reactions (SCARs) to drugs.
- Conditions
- Epidermal Necrolysis, Lyell Syndrome, Toxic Epidermal Necrolysis, Overlap Syndrome
- Trial name
- LYSYME (NCT04711200)
- Testing
- Adipose derived stromal cells intravenously injected
- Where
- France
- Volunteers
- 15 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Coronary Artery Disease, Diabete Type 2
DCB for CAD With Type 2 Diabetes
Patients with coronary artery disease (CAD) and type 2 diabetes mellitus (T2DM) often present with diffuse, complex lesions and a higher risk of in-stent restenosis after PCI.
- Trial name
- DCBinT2DM (NCT07009938)
- Testing
- Drug-Coated Balloon (DCB), Drug-Eluting Stent (DES) implantation
- Where
- 6 sites in China
- Volunteers
- 1,000 people
- Sponsor
- Shanghai 10th People's Hospital
Coronary Heart Disease (CHD)
AI-Driven Dynamic Prediction of Non-Target Lesion Progression After PCI: A Chinese Multicenter Cohort Study
Coronary artery disease remains a leading cause of global mortality. Although percutaneous coronary intervention (PCI) improves patient outcomes, the long-term risk of major adverse cardiovascular events (MACE) driven by the…
- Trial name
- VISION-PCI (NCT07312318)
- Testing
- percutaneous coronary intervention
- Where
- China
- Volunteers
- 12,000 people
- Sponsor
- China-Japan Friendship Hospital
Lipedema, Obesity
Comparison of Segmental Body Composition Characteristics in Lipedema and Obesity
The aim of this study is to compare the total and regional body composition characteristics of women with lipedema and women without lipedema who are matched for age and body mass index, as determined by the TANITA MC-580…
- Conditions
- Lipedema, Obesity, Body Mass Index, Bioelectrical Impedance Analysis
- Trial name
- NCT07878299
- Testing
- Bioelectrical Impedance Analysis, Numeric Rating Scale, Lower Extremity Functional Scale
- Where
- Turkey (Türkiye)
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey
Coronary Artery Disease, Acute Coronary Syndrome
Polymer-free Sirolimus Eluting Stent: Real-world Investigation of Safety and Outcomes
POLARIS is a prospective, single-centre, single-arm observational pilot registry evaluating the real-world safety and efficacy of the Focus np (Abluminus np, Concept Medical, Tampa, FL, USA) polymer-free sirolimus-eluting stent…
- Conditions
- Coronary Artery Disease, Acute Coronary Syndrome, Myocardial Infarction, Stent Thrombosis
- Trial name
- POLARIS (NCT07563231)
- Testing
- Polymer-free sirolimus-based submicron carrier-eluting stent Focus np (Abluminus np, Concept Medical, Tampa, FL, USA)
- Where
- Switzerland
- Volunteers
- 300 people
- Sponsor
- Dorian Garin
Penetrating Keratoplasty, Multiple Graft Failure
Subconjunctival Humira for Boston Keratoprosthesis
This trial is studying the safety and tolerability of receiving an injection of adalimumab (Humira) during the Boston Keratoprosthesis (KPro) surgery.
- Conditions
- Penetrating Keratoplasty, Multiple Graft Failure, Ocular Cicatricial Pemphigoid, Stevens-Johnson Syndrome
- Trial name
- NCT06926478
- Testing
- Adalimumab Injection
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Massachusetts Eye and Ear Infirmary
Peripheral Artery Disease, Critical Limb Ischemia
Temsirolimus Adventitial Delivery to Improve ANGioplasty and/or Atherectomy Revascularization Outcomes Below the Knee
A multicenter, randomized, double-blind, placebo-controlled trial to evaluate the effect of Temsirolimus Perivascular Injection 0.1 mg/mL on the incidence of ischemia-driven major amputation, clinically driven target lesion…
- Trial name
- TANGO-3 (NCT04433572)
- Testing
- Temsirolimus
- Where
- 2 sites in United States
- Volunteers
- 250 people
- Sponsor
- Mercator MedSystems, Inc.
Coronary Artery Disease
ANDREAS Registry (Assessment of Novel Drug-coated Balloon Revascularization: Effectiveness, Angiographic Outcomes, and Safety)
The primary objective of this protocol is to develop a comprehensive, multicenter international prospective registry to capture long-term clinical outcomes for adult patients undergoing percutaneous coronary intervention (PCI)…
- Trial name
- NCT07559903
- Where
- 19 sites in United States, Germany and 1 more
- Volunteers
- 5,000 people
- Sponsor
- Emory University
Plaque Type Psorisis, Non-pustular Palmoplantar Psoriasis
Clinical Study on the Medical Devices PROXERA PSOMED 20 and PROXERA PSOMED 40 for the Treatment of Plaque Psoriasis and Non-pustular Palmoplantar Psoriasis
This single-center interventional study was designed to evaluate the efficacy and safety of two CE-marked topical medical devices: PROXERA PSOMED 20 is being studied in participants with non-palmoplantar plaque psoriasis, while…
- Trial name
- PASI (NCT07545902)
- Testing
- PROXERA PSOMED 20 cream; PROXERA PSOMED 40 gel
- Where
- Italy
- Volunteers
- 35 people
- Sponsor
- ICIM International S.r.l.